Catalyst Pharmaceuticals, Inc. (CPRX) is a commercial-stage biopharmaceutical company that develops and commercializes therapies for patients with rare neuromuscular and neurological diseases.
The company reported a solid second-quarter result, with total revenues growing 87.5% year-over-year to an all-time high of $99.58 million. CPRX also raised its full-year 2023 total revenues forecast to be between $380 million and $390 million, indicating a 77% to 82% increase compared to 2022.
